FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1850-1851 April 24, 2008 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Clinical studies have become very expensive to conduct, and multiple sources of funding often support a single study. Biomedical journals routinely disclose all sources of funding of the research they publish; this has been standard practice at the Journal for many years. As funding mechanisms grow increasingly complex, however, it has become ever more challenging for editors to ensure the complete reporting of all sources of financial support.

Why is this important? Although the science in a submitted manuscript should be judged on its merits, one cannot fully appreciate a study's meaning without acknowledging the subtle biases in design and . . . [Full Text of this Article]

Source Information

This article (10.1056/NEJMe0802618) was published at www.nejm.org on April 2, 2008.

Related Letters:

Clarification of Funding of Early Lung Cancer Study
Henschke C.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:1862, Apr 24, 2008; published at www.nejm.org on Apr 2, 2008 (10.1056/NEJMc086128). Correspondence

This article has been cited by other articles:

• Hochman, M., Hochman, S., Bor, D., McCormick, D. (2008). News Media Coverage of Medication Research: Reporting Pharmaceutical Company Funding and Use of Generic Medication Names. JAMA 300: 1544-1550 [Abstract] [Full Text]  
• Bauchner, H. (2008). The continuing dilemma of competing interests. Arch. Dis. Child. 93: 643-643 [Full Text]